Avidity Biosciences, Inc. (RNA) investor relations documents from the company's IR site: 1 presentation, 5 press releases; latest deck 2026-08-13. Read in-app with summaries. First-party data.
Investor Presentation: Atrium Therapeutics is developing precision RNA medicines for rare cardiac diseases, with ATR 1072 (PRKAG2) and ATR 1086 (PLN) in its pipeline. The company has $1.5B cash.
| Published | Type | Document |
|---|---|---|
| 2026-08-13 | Presentation | Investor Presentation |
| 2026-08-13 | Press release | Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaborat |
| 2026-08-13 | Press release | Atrium Therapeutics Reports Second Quarter 2026 Financial Results |
| 2026-07-20 | Press release | Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-14 | Press release | Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR-1072 for Treatment of PRKAG2 |
| 2026-06-23 | Press release | Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
RNA overview · RNA earnings · RNA financials · RNA KPIs · RNA ownership · RNA peers · RNA filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.